{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:47:49Z","timestamp":1787510869413,"version":"build-2736575974"},"reference-count":41,"publisher":"Informa UK Limited","issue":"27","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Constellation Pharmaceuticals a MorphoSys Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2217\/fon-2022-0484","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T04:49:09Z","timestamp":1660193349000},"page":"2987-2997","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":41,"title":["Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire N","family":"Harrison","sequence":"first","affiliation":[{"name":"Guys & St Thomas\u2019 NHS Foundation Trust,Guy\u2019s Hospital,\rLondon,\rSE1 9RT,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine,Princess Margaret Cancer Centre,University of Toronto,\rToronto,\rON,\rM5G 1Z5,\rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T","family":"Gerds","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology,Cleveland Clinic Taussig Cancer Institute,\rCleveland,\rOH 44195,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Leukemia Service,Department of Medicine and Center for Hematologic Malignancies,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY 10065,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia,The University of Texas,\rMD Anderson Cancer Center,\rHouston,\rTX 77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-3981","authenticated-orcid":false,"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology,University of Michigan,\rAnn Arbor,\rMI 48109-5936,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"Clinical Investigation Center (INSERM CIC 1427),Universit\u00e9 Paris Cit\u00e9 and H\u00f4pital Saint-Louis,\rParis,\r75010,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center,UT Health San Antonio Cancer Center,\rSan Antonio,\rTX 78229-3900,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology,H. Lee Moffitt Cancer Center,\rTampa,\rFL 33612,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Hematology,Azienda Ospedaliero-Universitaria Careggi,\rFirenze,\r50139,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Department of Hematology,IRCCS Azienda Ospedaliero-Universitaria S. Orsola-Malpighi,\rBologna,\r40138,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cancer Prevention,Medical University of Silesia in Katowice,\rKatowice,\r40-055,\rPoland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-417X","authenticated-orcid":false,"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[{"name":"Department of Hematology,University Hospitals Leuven & Laboratory of Molecular Immunology (Rega Institute),\rKU Leuven,\rLeuven,\r3000,\rBelgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-6653","authenticated-orcid":false,"given":"Eric","family":"Jourdan","sequence":"additional","affiliation":[{"name":"Department of Hematology,C.H.U.,\rN\u00eemes,\r30029,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle J","family":"Wondergem","sequence":"additional","affiliation":[{"name":"Department of Hematology,Amsterdam University Medical Centers,\rAmsterdam,\r1081 HV,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[{"name":"Krukenberg Cancer Center,University Hospital Halle,\rHalle,\r06120,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-9700","authenticated-orcid":false,"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I with Hematology,Stem Cell Transplantation,Hemostaseology and Medical Oncology,Ordensklinikum Linz Elisabethinen & Johannes Kepler University Linz,\rLinz,\r4020,\rAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4619","authenticated-orcid":false,"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology,Hospital Cl\u00ednic Barcelona,\rBarcelona,\r08036,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-2906","authenticated-orcid":false,"given":"Andrea","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Hematology Unit,Azienda Ospedaliero Universitaria Maggiore della Carit\u00e0 di Novara,\rNovara,\r28100,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-3757","authenticated-orcid":false,"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology,Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,\rNew York,\rNY 10029,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-1002","authenticated-orcid":false,"given":"Adam J","family":"Mead","sequence":"additional","affiliation":[{"name":"MRC Molecular Haematology Unit,MRC Weatherall Institute of Molecular Medicine,John Radcliffe Hospital,University of Oxford,\rOxford,\rOX3 9DX,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Akhani","sequence":"additional","affiliation":[{"name":"MorphoSys AG, Planegg,\r82152,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sheikine","sequence":"additional","affiliation":[{"name":"Constellation Pharmaceuticals, Inc.,a MorphoSys Company,\rBoston,\rMA 02110,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Colak","sequence":"additional","affiliation":[{"name":"Constellation Pharmaceuticals, Inc.,a MorphoSys Company,\rBoston,\rMA 02110,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology,Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,\rNew York,\rNY 10029,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S51800"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0018-z"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.233"},{"key":"e_1_3_6_9_1","unstructured":"United States Food & Drug Administration . JAKAFI (ruxolitinib) prescribing information (2021). www.jakafi.com\/pdf\/prescribing-information.pdf"},{"key":"e_1_3_6_10_1","unstructured":"United States Food & Drug Administration . INREBIC (fedratinib) prescribing information (2021). www.celgene.com\/content\/uploads\/inrebic-pi.pdf"},{"key":"e_1_3_6_11_1","unstructured":"United States Food & Drug Administration . VONJO (pacritinib) prescribing information (2022). www.ctibiopharma.com\/VONJO_USPI.pdf"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_6_16_1","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: myeloproliferative neoplasms. Version 1 (2022). https:\/\/nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00506"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.286"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.262691"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1741381"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25230"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32664"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0115"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522163112"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11339.1"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.024"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1411701111"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01882"},{"key":"e_1_3_6_33_1","volume-title":"63rd ASH Annual Meeting & Exposition","author":"Blum KA","year":"2021","unstructured":"Blum KA , SupkoJG, MarisMet al. PK and PD assessment of BET inhibitor pelabresib (CPI-0610) in patients with relapsed or refractory lymphoma: findings from a phase 1 study. Presented at: 63rd ASH Annual Meeting & Exposition. GA, USA (11\u201314 December 2021)."},{"key":"e_1_3_6_34_1","volume-title":"63rd ASH Annual Meeting & Exposition.","author":"Verstovsek S","year":"2021","unstructured":"Verstovsek S , SalamaME, MascarenhasJet al. Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis \u2013 preliminary data. Presented at: 63rd ASH Annual Meeting & Exposition.GA, USA (11\u201314 December 2021)."},{"key":"e_1_3_6_35_1","volume-title":"62nd ASH Annual Meeting & Exposition.","author":"Mascarenhas J","year":"2020","unstructured":"Mascarenhas J , HarrisonC, PatriarcaAet al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: update of MANIFEST phase 2 study. Presented at: 62nd ASH Annual Meeting & Exposition. (5-8 December 2020). (Virtual)"},{"key":"e_1_3_6_36_1","volume-title":"63rd ASH Annual Meeting & Exposition","author":"Kremyanskaya M","year":"2021","unstructured":"Kremyanskaya M , MascarenhasJ, PalandriFet al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis \u2013 update of clinical and translational data from the ongoing MANIFEST trial. Presented at: 63rd ASH Annual Meeting & Exposition. GA, USA (11\u201314 December 2021)."},{"key":"e_1_3_6_37_1","volume-title":"European Hematology Association 2021 Virtual Congress","author":"Verstovsek S","year":"2021","unstructured":"Verstovsek S , KremyanskayaM, MascarenhasJet al. Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: Interim results from MANIFEST phase 2 study. Presented at: European Hematology Association 2021 Virtual Congress. (9\u201317 June 2021). (Virtual)"},{"key":"e_1_3_6_38_1","volume-title":"European Hematology Association 2021 Virtual Congress","author":"Keller P","year":"2021","unstructured":"Keller P , CuiJ, MertzJet al. BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients. Presented at: European Hematology Association 2021 Virtual Congress. (9\u201317 June 2021). (Virtual)"},{"issue":"3","key":"e_1_3_6_39_1","first-page":"1769","article-title":"MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of pelabresib (CPI-0610) and ruxolitinib versus placebo and ruxolitinib in JAK inhibitor-naive myelofibrosis patients","volume":"6","author":"Harrison C","year":"2022","unstructured":"Harrison C , RampalRK, GuptaVet al. MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of pelabresib (CPI-0610) and ruxolitinib versus placebo and ruxolitinib in JAK inhibitor-naive myelofibrosis patients. HemaSphere.6(S3), 1769\u20131770 (2022).","journal-title":"HemaSphere."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-414631"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0642-0"},{"key":"e_1_3_6_43_1","unstructured":"Constellation Pharmaceuticals . Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04603495"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:43:45Z","timestamp":1719110625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":41,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2217\/fon-2022-0484"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0484","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}